Menu
Search
|

Menu

Close
X

Puma Biotechnology Inc PBYI.OQ (NASDAQ Stock Exchange Global Select Market)

68.25 USD
+2.10 (+3.17%)
As of Feb 23
chart
Previous Close 66.15
Open 66.15
Volume 321,970
3m Avg Volume 262,856
Today’s High 68.60
Today’s Low 61.70
52 Week High 136.90
52 Week Low 28.35
Shares Outstanding (mil) 37.21
Market Capitalization (mil) 4,516.76
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
6
FY16
0
FY15
0
EPS (USD)
FY17
-6.151
FY16
-8.294
FY15
-7.445
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
37.46
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-224.57
14.43
Return on Equity (TTM)
vs sector
-233.95
16.13

EXECUTIVE LEADERSHIP

Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $705,994.00
Bonus: $542,707.00
Charles Eyler
Senior Vice President - Finance and Administration, Treasurer, Since 2011
Salary: $384,244.00
Bonus: $207,255.00
Richard Bryce
Chief Scientific Officer, Chief Medical Officer, Since 2017
Salary: $395,431.00
Bonus: $225,346.00
Steven Lo
Chief Commercial Officer, Since 2015
Salary: $435,625.00
Bonus: $270,143.00
Jay Moyes
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10880 Wilshire Blvd Ste 2150
LOS ANGELES   CA   90024-4106

Phone: +1424.2486500

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

SPONSORED STORIES